A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2011-09-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-011-1735-4PMID 21909644
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemotherapy in epithelial ovarian cancer.

  2011cited by this paper
• Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study

  2009cited by this paper
• Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (A

  2009cited by this paper
• Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.

  2008cited by this paper
• Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?

  2006cited by this paper
• Long intracellular retention of 4′-thio-arabinofuranosylcytosine 5′-triphosphate as a critical factor for the anti-solid tumor activity of 4′-thio-arabinofuranosylcytosine

  2006cited by this paper
• Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

  2006cited by this paper
• A three schedule phase I trial of CP-4055, weekly and q2 weeks in patients with advanced or metastatic solid tumors.

  2006cited by this paper
• Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival.

  2005cited by this paper
• NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS

  2004cited by this paper
• Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.

  2004cited by this paper
• Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.

  2004cited by this paper
• Carcinoma of the Ovary

  2003cited by this paper
• Relapsed ovarian cancer: challenges and management strategies for a chronic disease.

  2002cited by this paper
• Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.

  2001cited by this paper
• Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.

  1999cited by this paper
• Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings.

  1999cited by this paper
• Ara-C: cellular and molecular pharmacology.

  1998cited by this paper
• Cellular pharmacodynamics of anticancer drugs.

  1993cited by this paper
• 1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview.

  1992cited by this paper
• Effects of 1-beta-D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution.

  1990cited by this paper
• High dose cytarabine: a review.

  1988cited by this paper
• Cytarabine and cisplatin in advanced malignant melanoma.

  1986cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper
• Correlation of response to 1-beta-D-arabinofuranosyl cytosine and metabolism of drug by tumor.

  1976cited by this paper

• Advanced Photocatalytic Degradation of Cytarabine from Pharmaceutical Wastewaters

  2024cites this paper
• Emerging insights on drug delivery by fatty acid mediated synthesis of lipophilic prodrugs as novel nanomedicines.

  2020cites this paper
• Drug–Lipid Conjugates for Enhanced Oral Drug Delivery

  2019cites this paper
• Lipidic prodrug approach for improved oral drug delivery and therapy

  2018cites this paper
• Chemotherapy agent‐unsaturated fatty acid prodrugs and prodrug‐nanoplatforms for cancer chemotherapy

  2017cites this paper
• Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy.

  2016cites this paper
• Novel Developments in the Use of Antimetabolites

  2014cites this paper
• Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.

  2013cites this paper
• Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications.

  2013cites this paper
• Gemcitabine versus modified gemcitabine : a review of several promising chemical modifications

  2013cites this paper
• Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts.

  2013cites this paper